PPA
ARQT icon

Parametric Portfolio Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Parametric Portfolio Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$350K Sell
18,155
-4,049
-18% -$68.5K ﹤0.01% 3226
2021
Q4 		$461K Buy
+22,204
New +$442K ﹤0.01% 3108
2021
Q2 		– Sell
-8,010
Closed -$232K – 3561
2021
Q1 		$232K Buy
+8,010
New +$250K ﹤0.01% 3818

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parametric Portfolio Associates's ARQT Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Arcutis Biotherapeutics (ARQT) stake by 18% in Q1 2022, selling an estimated $68.5K and leaving 18,155 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #3226.

Parametric Portfolio Associates first reported a position in ARQT in Q1 2021 and has held it in 3 quarters since. The position peaked at $461K in Q4 2021. 107 funds tracked by Wall St. Rank hold ARQT as of Q1 2022.

  • Parametric Portfolio Associates held 18,155 shares of Arcutis Biotherapeutics worth $350K as of Q1 2022.
  • Parametric Portfolio Associates sold 4,049 Arcutis Biotherapeutics shares in Q1 2022, an estimated $68.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3226 holding.
  • Parametric Portfolio Associates first reported a position in Arcutis Biotherapeutics in Q1 2021 and has held it in 3 quarters since.
  • Parametric Portfolio Associates's Arcutis Biotherapeutics position peaked at $461K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.